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Background: Autoimmune and inflammatory mechanisms in psychotic disorders have attracted increasing scientific
attention in recent years. In this regard, we performed routine cerebrospinal fluid (CSF) basic diagnostics and CSF/serum
analyses for antibodies directed against neuronal intracellular and surface antigens in psychotic patients. In this context,
the patient presented in this paper was diagnosed.
Case presentation: We present the case of a 20-year-old female patient with a first episode of a drug-induced psychotic
syndrome but without neurological deficits. Further investigations showed a reproducible low-titre positive anti-Yo
reactivity in the CSF and serum with two independent immunoblot assays. Magnetic resonance imaging showed
frontoparietal and cerebellar atrophy. On [18F]fluorodeoxyglucose positron emission tomography, a mild cerebellar
hypometabolism was found. No underlying tumor was detected.
Conclusion: Despite the presence of anti-Yo reactivity, the diagnostic criteria for a paraneoplastic neurological syndrome
were not fulfilled. Previously published data indicate the possible association between low-titer antibodies against
intracellular localized, onconeural antigens, and psychotic disorders. Large prospective studies that investigate the
prevalence and clinical significance of antibodies against intracellular onconeural antigens in psychiatry are needed.
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In recent years, discrete immunological encephalopathy
(IE) has been increasingly recognized as a possible cause
of psychotic and affective disorders [1,2]. In the majority
of cases, other more or less subtle findings, such as mag-
netic resonance imaging (MRI), electroencephalography
(EEG) pathology, or neurological soft signs point to an
“organic cause” of the psychotic syndrome; however, a
number of case reports in the literature indicate that IE
is identified in psychotic cases without these findings [3]
(Endres D, Perlov E, Stich O, Tebartz van Elst L: Steroid
responsive encephalopathy associated with autoimmune
thyroiditis (SREAT) - presenting as major depression, in
preparation). For this reason, in our institution, we have* Correspondence: tebartzvanelst@uniklinik-freiburg.de
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unless otherwise stated.been offering serum and cerebrospinal fluid (CSF) ana-
lyses for antibodies directed against neuronal intracellu-
lar and surface antigens as well as CSF basic diagnostics
as a routine diagnostic measure to all psychotic patients
since 2009. In this paper, we report the case of a schi-
zoaffective patient with low-titer anti-Yo reactivity in the
CSF and serum, respectively, whom we have identified
in this context. Anti-Yo antibodies belong to the so-
called “well-characterized” paraneoplastic antibodies
against intracellular onconeuronal antigens [4]. They tar-
get the Purkinje cells of the cerebellum and are therefore
called the Purkinje cell cytoplasmic antibodies type 1 [5].
The anti-Yo syndrome in association with high-titer
anti-Yo antibodies is the most common reason for para-
neoplastic cerebellar degeneration (PCD). In PCD, global
cerebellar deficits typically arise sub-acutely and pro-
gress over months. Disturbances in cognitive impair-
ment with memory deficits and emotional instability areThis is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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associated with gynecological (typically ovarian but also
breast, uterine, or tubal) carcinomas [8].
Case presentation
Clinical presentation
We present the case of a 20-year-old female high school
graduate with an acute schizoaffective syndrome. She
complained of auditory (contrasting voices) and visual
(images on the sky or migratory objects) hallucinations.
She also experienced a sensation as if the wind was
blowing into her face (delusional atmosphere), and she
believed this to be a sign from her unfamiliar environ-
ment (delusion of influence). She interpreted these signs
as a call for suicide. Moreover, she reported depressive
symptoms, such as sadness, loss of motivation and en-
ergy, social withdrawal, insomnia, and lack of appetite.
Her capability to think or concentrate adequately was re-
duced, and her overall thinking processes were slow.
After being admitted to the hospital, she also com-
plained of a headache. Comprehensive medical and
neurological examinations indicated no relevant abnor-
malities, with the exception of a mild dysdiadochokinesia
and a moderate hirsutism.
Previous medical history
This was the first episode of psychiatric symptoms for
the patient. She had no history of complications during
pregnancy or delivery, and early development was unre-
markable and without any evidence of a neurodevelopmen-
tal disorder. She was socially integrated and successfully
completed her academic career. However, the patient re-
ported a diffuse episode of earlier intermediate gait dis-
order resembling ataxia. The onset of symptoms was
temporally related to short-term consumption of hallu-
cinogenic mushrooms and rare but repeated low-dose
cannabis abuse. The psychotic symptoms developed
over a subsequent five-month period prior to admission
to our hospital despite drug abstinence. No tumor in
the patient’s own history was known, but a family his-
tory of breast cancer was positive (grandmother: breast
cancer at age of 30 years).
Diagnostic results
Serum and CSF investigations with the “ravo blot” using
recombinant onconeural antigens as a substrate showed
a weak but reproducible anti-Yo specific reactivity [9]
(ravo blot: immunoblot using recombinant onconeural
antigens as a substrate; ravo Diagnostika, Freiburg,
Germany [www.ravo.de/de/Produkte/ravo_pns_blot_zu_
immuno_verst.php]) but no evidence of an anti-Yo spe-
cific intrathecal antibody synthesis. In the Euroimmun
immunblot for serum and CSF an anti-Yo specific, re-
activity was found too. Moreover, a weak anti-Ma2-reactivity was found in the serum (without confirmation
in the ravo blot; Euroimmun blot: EUROLINE –Neur-
onal Antigens Profile 4, Euroimmun, Luebeck, Germany
[www.euroimmun.de/index.php?id=29&L=1]). No anti-
bodies were found against other intracellular onconeural
antigens (Hu, CV2/CRMP5, Ri, Ma1, SOX1) or intracel-
lular synaptic antigens (GAD, amphiphysin) in the serum.
Immunological screening in the serum for rheumatoid
autoimmune disorders was negative. In addition, sero-
logical analysis showed no exposure to neurotropic infec-
tious agents, such as borrelia, lues, HIV, and FSME. CSF
analysis was unremarkable (white blood cell count: 1/μL,
no dysfunction of the lood-brain-barrier [albumin-quotient:
4.1], no intrathecal IgG synthesis). Moreover, no antibodies
against neuronal cell surface antigens (NMDAR, AMPA-1/
2-R, GABA-B-R, VGKC-complex [LGI1, Caspr2]) were
found in the CSF. EEG was normal, whereas MRI illus-
trated a discrete frontoparietal and cerebellar atrophy,
which was clearly abnormal given the young age of the pa-
tient (Figure 1). In addition, a small arachnoidal cyst was
detected in the left temporopolar region. The arachnoidal
cyst is an incidental finding without a substantial space-
occupying effect; therefore, it is not very likely that it leads
to clinical symptoms. [18F]fluorodeoxyglucose positron
emission tomography (FDG-PET) depicted a mild, border-
line significant cerebellar hypometabolism. Otherwise, the
PET was unremarkable. In particular, mesiotemporal hyper-
metabolism, which is typically seen in limbic encephalitis,
was not observed (Figure 2). The broad diagnostic work-up
in search for primary tumors remained unremarkable
(breast ultrasonography, whole-body FDG-PET/computed
tomography, chest MRI). However, a polycystic ovary syn-
drome (with secondary amenorrhea, polycystic ovaries, and
hirsutism) was diagnosed.
Therapeutic and clinical course
On a clinical basis, we started a combined therapy with
risperidon (4mg/day) and quetiapine (300mg/day). Psych-
otic symptoms declined under medical treatment after
one to two weeks. Depressive symptoms, such as loss of
motivation or energy and a diminished ability to think or
concentrate, deteriorated. Interestingly, anti-Yo reactivity
in the serum disappeared four months after the first posi-
tive result without any immunosuppressive treatment.
Conclusions
Characteristics of our case report
We present the case of a 20-year-old woman suffering
from a schizoaffective syndrome. Laboratory diagnostics
showed a weak and transient anti-Yo-specific reactivity
in the CSF and serum, respectively. This abnormal la-
boratory finding was confirmed by examination of con-
secutive samples with two independent immunoblot
assays using highly specific and recombinant onconeural
Figure 1 Magnetic resonance imaging shows a slight but atypical age-related frontoparietal and cerebellar atrophy.
Endres et al. BMC Psychiatry  (2015) 15:112 Page 3 of 5antigens that showed reproducible anti-Yo reactivity
until its spontaneous disappearance after fourth months.
MRI depicted a slight but clearly abnormal frontoparieto-
cerebellar atrophy, and FDG-PET detected a hypometabo-
lism of both cerebellar hemispheres. While assuming that
the psychiatric symptoms were triggered by the transient
drug abuse is plausible, according to present knowledge
and thinking, it does not explain the MRI and FDG-PET
findings nor the anti-Yo reactivity.
Diagnostic assessment and differential diagnosis
Paraneoplastic neurological syndromes (PNS) are
characterized by high and permanent concentrationsFigure 2 [18F]fluorodeoxyglucose positron emission tomography (FDG-PET
Otherwise, the PET was unremarkable. No mesiotemporal hypermetabolism
performed at the Department of Nuclear Medicine of the University Hospit
Electronics, The Netherlands). Upper and lower row images show transaxial FD
FDG uptake (colour-coded Z-score, compared to age-matched healthy controof antineuronal antibodies and are frequently associ-
ated with intrathecal antigen-specific antibody synthe-
sis, inflammatory CSF changes, distinct neurological
syndromes, and, very often but not always, the detec-
tion of cancer during further diagnostic work-up
[8,10]. PCD is a well-established PNS. Our patient
here showed suspicious findings in the cerebral MRI
and FDG-PET for this syndrome, although additional
frontoparietal atrophy is uncommon. At the time of
imaging acquisition, no clinical cerebellar signs were
observed, and the patient’s history indicated only one
transient episode of ataxia. Interestingly, cerebellar dys-
function might be associated with cognitive deficits,) showed a mild, borderline significant cerebellar hypometabolism.
as typically seen in limbic encephalitis was observed. FDG-PET was
al Freiburg after injection of 320 MBq FDG (Gemini True Flight, Philips
G-PET images and 3D surface projections of regions with decreased
ls), respectively.
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drome”), and even psychotic symptoms [11,12]. In our
case, the diagnostic criteria for PNS recommended by an
international panel of PNS experts were not fulfilled [10].
Following Graus et al. [10], we can postulate a “possible
non-classical PNS”, but the low-titer and the transient
presence of anti-Yo reactivity argues against this hypoth-
esis. The most probable primary diagnosis for our patient
is a drug-induced psychotic disorder, possibly based on an
increased vulnerability to short-term drug consumption in
the context of the structural and functional cerebral/cere-
bellar changes depicted in the MRI and FDG-PET, re-
spectively. We speculate that the temporary presence of
anti-Yo reactivity might mirror an underlying auto-
immune process. However, the role of onconeural anti-
bodies in the pathogenesis of PCD remains unclear
because of the predominant intracellular localization of
their targets [8,10,13]. Other neurodegenerative disorders
with frontoparietal atrophy, such as corticobasal degener-
ation [14] or with parieto-(occipital) atrophy, such as pos-
terior cortical atrophy [15], are unlikely because of the
young age of the patient, her family history, and the other-
wise normal FDG-PET scan. Conversely, we found no
clinical clue that the cerebellar hypometabolism and at-
rophy might have been caused by an unrelated disease
(e.g., neurodegenerative disorders such as SCA or
MSA-C).
Why this case report? The role of intracellular
antineuronal antibodies in psychiatry
Why do we report this case even though we were unable
to diagnose paraneoplastic anti-Yo syndrome? One rea-
son is to illustrate the complexity of the clinical work-up
in this rapidly evolving field of research. While drug in-
duced psychosis might still be the most likely diagnosis
for our patient, we still wonder about the causal role of
our findings of transient anti-Yo-antibodies, fronto-
parieto-cerebellar atrophy, and the cerebellar PET
finding. Do these results indicate that we can stop anti-
psychotic medication once the antibodies disappeared?
Do we have to watch out for future gynecological tumors?
One might speculate that a paraneoplastic psychotic syn-
drome heralded a not-yet detectable gynecological tumor.
In this constellation, a paraneoplastic psychotic syndrome
could function as a life-saving warning sign. Furthermore,
which therapeutic approach is the best in such constella-
tions? Should we stick to symptomatic antipsychotic
medication or try immune-modulating interventions? All
of these questions are important but unanswered to date.
A growing body of knowledge focuses on the associ-
ation between psychiatric diseases and autoimmune phe-
nomena, including the detection of antibodies against
intracellular neuronal antigens. Remarkably, Laadhar
et al. reported confirmed well-characterized antineuronalantibodies in five of 103 psychiatric inpatients (4.9%)
who were routinely screened for antineuronal anti-
bodies; they found none in the control group. Aside
from three anti-Yo cases (one in schizophrenia, two in
bipolar disorder), two schizophrenic patients with
anti-Ri reactivity were detected. Interestingly, none of
the antibody-positive patients developed a tumor, at
least up to a follow-up period of five years [16]. From
a pathophysiological point of view, cytotoxic T-cell ac-
tivity and not autoantibodies is assumed to be respon-
sible for neuronal damage in classical PNS [17].
Therefore, we speculate that misled T-cell responses
might be a different pathogenetic mechanism in a sub-
group of antineural antibody-associated psychotic sny-
dromes. This view might lead to alternative treatment
concepts [16].
In summary, in accordance with the study of Laad-
har et al. [16], our case report indicates that reactivity
against intracellular neuronal antigens might be asso-
ciated with psychiatric symptoms without a clinical
manifestation of PNS or cancer. Similar results with
low-antibody titers are known from anti-N-Methyl-D-
aspartate-receptor (NMDAR) antibodies in schizo-
phrenia [18]. However, in a large study investigating
the prevalence of anti-NMDAR antibodies, unexpect-
edly high rates of serum positivity were also found in
schizophrenic patients (8.6%), as well as in healthy
control subjects (10.8%) [19], a result that challenges
the clinical significance of isolated serum antibodies
without clinical deficits or signs of a disruption of the
blood-brain barrier. As in the case of Hashimoto en-
cephalitis, NMDAR antibodies alone might not be the
critical pathophysiological agent but are just a herald-
ing marker of a yet unknown immune process that
causes neuronal network dysfunction and psychiatric
symptoms as a consequence.Conclusion
The currently available data on the prevalence of anti-
bodies against intracellular onconeural antigens and
their relevance in psychiatric disorders are sparse.
Therefore, case reports are essential to gain an improved
understanding of the possible links between structural
brain changes, antibody findings, and clinical symptoms.
Large, prospective studies that examine the prevalence
and possible pathophysiological role of antineuronal
antibodies in psychiatry are needed.
Consent
Written informed consent was obtained from the patient
for the publication of this case report and any accom-
panying images. A copy of the written consent is avail-
able for review by the editor of this journal.
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